TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05915754

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Posterior oblique sling strengthening exercises
Description: Treatment consists of treatment A plus the intervention program of POSS consisted of four different exercises utilizing activation of the POSS. The intervention program focuses on one specific exercise each week that will progress in difficulty over the 4 weeks. The equipment used in the exercise progression included a blue, latex-free, medium-resistance theraband (TB), and the final exercise of the progression will include the use of a step stool. The TB will be used to increase the activation of the latissimus dorsi while simultaneously performing lower-extremity exercise to increase gluteal muscle involvement. The exercises are to be used in the 4-week progression.
Study: NCT05303883

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pediatric Constrained Induced Movement Therapy
Description: Constraint of the child's less-impaired upper extremity for first 17 days of treatment. Children wear a removable, lightweight constraint for the first 17 of 20 therapy sessions.
Study: NCT06192563

Intervention type: DRUG
Intervention: Dupilumab
Description: Subcutaneous injection, standard of care as prescribed by treating physician (no investigational drug provided)
Study: NCT04671641

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: radiofrequency ablation
Description: ultrasound-guided radiofrequency ablation is performed to treat varicose veins patients

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: radiofrequency ablation
Description: ultrasound-guided radiofrequency ablation is performed to treat varicose veins patients
Study: NCT05131386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: ET-743, Yondelis (vials of 1 mg). Route of administration: intravenous infusion
Study: NCT04911933

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Therapy
Description: There will be systemic family psychotherapy sessions every two weeks. Families and individuals who require a more intensive service will be referred to a higher level of care.
Study: NCT05577611

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Basic chemotherapy + UCB transplantation
Description: The basic chemotherapy regimen was the same as that of the control group~UCB micro transplantation scheme:~Aza 100mg, 75mg/m2/d, IVGTT, D-10 to D-4~Ara-C 1000mg/m2/q12h, IVGTT, D-3 to D-2~Single non consanguineous umbilical cord blood (NC \> 1.5 \* 10 \^ 7 / kg), IVGTT, D0~Bone marrow aspiration smear, MRD and bone marrow chimerism were detected on D14, d30 and D60 after transplantation.
Study: NCT06356116

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: During hospitalization, physical therapist visits the patient once or twice on day one or two post-operative (treatments including bedside standing, ambulation, stepping, active-assisted range of motion exercises).~Educational material will be given at discharge from hospital.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accelerated rehabilitation
Description: Physical therapist visits 5 times during hospitalization, including~1. Pre-operatively: instruction regarding range of motion exercises, use of assistive device.~2. Post-operative day zero: bedside standing, ambulation, stepping, active-assisted range of motion exercises.~3. Post-operative day one: visit #1 continuing the day-zero exercises;~4. Post-operative day one: visit #2 mini-squat against wall; stair negotiation training (1/2 flight).~5. Post-operative day two: continuing the day-zero exercises; stair negotiation (1 flight); discharge from hospital in the afternoon.~After discharge from hospital: post-operative day three \~ week 4: telerehabilitation
Study: NCT06000072

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core Exercise Program
Description: Core exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Core Exercise Program
Description: Core exercises
Study: NCT04812951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CycloSPORINE Ophthalmic 0.1% Ophthalmic Emulsion
Description: one cyclosporine 0.1% eye drop twice a day for 30 preoperative days

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cationorm eye drops
Description: one cationorm eye drop twice a day for 30 preoperative days
Study: NCT04713371

Intervention type: DRUG
Group type: OTHER
Intervention: Keytruda Injectable Product
Description: Keytruda (pembrolizumab): PD-1 inhibitor antibody~Injectable 50mg/mL, only 2 mL injected.

Intervention type: DRUG
Group type: OTHER
Intervention: Yervoy Injectable Product
Description: Yervoy (ipilimumab): Anti-CTLA-4 antibody~Injectable 5mg/mL, only 2 mL injected.

Intervention type: DRUG
Group type: OTHER
Intervention: Cytoxan
Description: Injectable 250mg/m2, only 1 mL injected. Oral low dose cyclophosphamide: 50mg once daily pill for 5 days prior to first treatment, 3 days prior to 2nd and 3rd treatment.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cryosurgical freezing (cryosurgery)
Description: Cryosurgery, also known as cryoablation, for metastatic cancer works by freezing the cancer cells inside the tumor. Cryoablation will release intact antigens to prime the immune system.

Intervention type: DRUG
Group type: OTHER
Intervention: GM-CSF Injectable
Description: Daily injection administered subcutaneously. 250 mcg daily injections for a total of 25 days post after each treatment.
Study: NCT05496816

Intervention type: DIAGNOSTIC_TEST
Intervention: CAC in septic patients
Description: Data collected included demographic parameters, comorbidities, vasopressors requirement, laboratory findings, in-hospital mortality scoring and diagnostic colagulation scores. Demographic parameters were taken on the day of admission, all other variables were taken on the day of admission to the ICU and on the day of initiation of invasive mechanical ventilation or on the day of discharge from the ICU.~Demographic parameters included age and sex of the patient, followed by comorbidities which was marked with Yes or No on the day of admission in the ICU. Mortality was assessed according to the qSOFA score and vasopressor requirements on the day of admission and on the day of initation of invasive mechanical ventilation or on the day of discharge. Laboratory analysis included analysis of platelets, neutrophils, lymphocytes, PCT, CRP, fibrinogen, D-dimer on the day of admission and on the day of initation of invasive mechanical ventilation or on the day of discharge.

Intervention type: DIAGNOSTIC_TEST
Intervention: CAC in septic patients
Description: Data collected included demographic parameters, comorbidities, vasopressors requirement, laboratory findings, in-hospital mortality scoring and diagnostic colagulation scores. Demographic parameters were taken on the day of admission, all other variables were taken on the day of admission to the ICU and on the day of initiation of invasive mechanical ventilation or on the day of discharge from the ICU.~Demographic parameters included age and sex of the patient, followed by comorbidities which was marked with Yes or No on the day of admission in the ICU. Mortality was assessed according to the qSOFA score and vasopressor requirements on the day of admission and on the day of initation of invasive mechanical ventilation or on the day of discharge. Laboratory analysis included analysis of platelets, neutrophils, lymphocytes, PCT, CRP, fibrinogen, D-dimer on the day of admission and on the day of initation of invasive mechanical ventilation or on the day of discharge.
Study: NCT05373381

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplemental High Fat Low Carbohydrate (sHFLC) + KetoPhyt
Description: Following a screening period, subjects will adhere to the sHFLC + KetoPhyt diet for six 4-week cycles. Patients will receive dietary advice from a Registered Dietitian (RD) to allow for the design of personalized meal plans maintaining carbohydrates up to 33% of total caloric intake, and be asked to maintain a daily dietary log. To assist patients in understanding, monitoring and controlling their dietary choices to maintain a low carbohydrate diet, they will be trained and receive assistance on the use of an online tool for tracking nutrition \[Healthtrac\].
Study: NCT05653635

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Simultaneous-integrated boost with IMRT
Description: Simultaneous-integrated boost guided by FDOPA-PET
Study: NCT05981495

Intervention type: DEVICE
Intervention: NanoDetect-TB
Description: This study of the NanoDetect-TB investigational device will test plasma and serum samples from TB suspects. There is no intervention for the subjects and there will be a single visit blood draw.
Study: NCT06415214

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-7535
Description: HRS-7535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-7535
Description: HRS-7535
Study: NCT06044610

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GENPOP Passive dehydration (75% reduction in fluid intake
Description: Over 24-hours

Intervention type: OTHER
Group type: OTHER
Intervention: GENPOP Ad lib fluid intake
Description: Over 24 hours

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EXERCISE without fluid replacement
Description: 90-min standard cycling exercise trial in heat chamber

Intervention type: OTHER
Group type: OTHER
Intervention: EXERCISE with fluid replacement
Description: 90-min standard cycling exercise trial in heat chamber
Study: NCT05676190

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CIK combined with chemotherapy group
Description: Combination of chemotherapy and autologous cytokine induced killer cells

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CIK combined immunotherapy group
Description: Combination of immunotherapy and autologous cytokine induced killer cells

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CIK combined targeted therapy group
Description: Combination of targeted therapy and autologous cytokine induced killer cells

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CIK in combination with other therapies
Description: CIK combined with any two or three of them (i.e. chemotherapy, immunotherapy and targeted therapy)
Study: NCT06486987

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Constraint induced movement therapy delivered by televideo
Description: In-home Constraint induced movement therapy delivered by a therapist participating by televideo
Study: NCT06170593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Injection
Description: 0.1mL of triamcinolone 1% solution per lesion
Study: NCT04866069

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 vaccine
Description: Adjuvanted inactivated vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 vaccine
Description: Adjuvanted inactivated vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% NaCl
Study: NCT05319288

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: In DPOG, motion style acupuncture would be used; in LPMG, Traditional Chinese Medicine acupuncture is used.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: In DPOG, motion style acupuncture would be used; in LPMG, Traditional Chinese Medicine acupuncture is used.
Study: NCT04757727

Intervention type: OTHER
Intervention: Decriptive study of EDB
Description: data on EDB will be register
Study: NCT04848337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib 20 mg orally daily.
Study: NCT05540821

Intervention type: DIAGNOSTIC_TEST
Intervention: Hysterosalpingo-contrast sonography and sonoPODography
Description: Before operation, phloroglucinol 40mg of antispasmolysis was injected intramuscular, and then cervical dilation was performed according to aseptic operation requirements. A 12G double-lumen catheter was inserted into the uterine cavity, and 1.5-1.8ml of normal saline was injected into the sacculus.~Transvaginal 2/3/4D hysterosalpingo-contrast sonography: One operator extracted 2ml of Sonovue and injected 18ml of normal saline through a dual-lumen catheter, and the other operator started the four-dimensional ultrasound mode to collect dynamic volume data.~sonoPODography: Sterile saline was injected into the intrauterine cavity, with an upper limit of 20ml. The normal saline flowed from the intrauterine cavity into the pelvic cavity through the bilateral fallopian tubes, forming a good acoustic window. Pelvic observation was then performed.
Study: NCT06467552

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: The entire process is carried out according to Severance Hospital surgical protocols.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nucare Curact group
Description: The entire process is carried out according to Severance Hospital surgical protocols. The patients of control group will receive education from the research team about the importance of nutrition and exercise before and after surgery. In addition, the patients of control group will be instructed to take up to 4 doses of the nutritional supplement (Nucare Curact provided by DAESANG Wellife Inc.) per day for approximately 2 weeks before surgery and for about 4 weeks after surgery.
Study: NCT05707455

Intervention type: OTHER
Intervention: evaluating blood levels of hemoglobin, hematocrit, red blood cell count, mean corpuscular volume, mean corpuscular hemoglobin concentration, serum transferrin and serum ferritin.
Description: evaluating blood levels of hemoglobin, hematocrit, red blood cell count, mean corpuscular volume, mean corpuscular hemoglobin concentration, serum transferrin and serum ferritin.

Intervention type: OTHER
Intervention: evaluating blood levels of hemoglobin, hematocrit, red blood cell count, mean corpuscular volume, mean corpuscular hemoglobin concentration, serum transferrin and serum ferritin.
Description: evaluating blood levels of hemoglobin, hematocrit, red blood cell count, mean corpuscular volume, mean corpuscular hemoglobin concentration, serum transferrin and serum ferritin.
Study: NCT06422338

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IMCI-enhanced by sTREM-1 levels (SoC + sTREM-1 POC)
Description: IMCI-guidelines (standard of care) + Point-Of-Care Rapid Triage Test (POC-RTT) based on sTREM-1 quantification
Study: NCT05025280

Intervention type: OTHER
Intervention: Adolescent/Adult Sensory Profile Questionnaire
Description: The Adolescent/Adult Sensory Profile Questionnaire (AASP), was developed based on Dunn's model of sensory processing. It is a 60-item self-assessment questionnaire that evaluates behavioral patterns related to sensory processing. The questionnaire consists of six different subsections such as taste/smell processing, movement processing, visual processing, touch processing, auditory processing, and activity level. According to the answers given, individuals are evaluated in 4 quartiles as low registration, sensory sensitivity, sensation avoiding, and sensation seeking.

Intervention type: OTHER
Intervention: Adolescent/Adult Sensory Profile Questionnaire
Description: The Adolescent/Adult Sensory Profile Questionnaire (AASP), was developed based on Dunn's model of sensory processing. It is a 60-item self-assessment questionnaire that evaluates behavioral patterns related to sensory processing. The questionnaire consists of six different subsections such as taste/smell processing, movement processing, visual processing, touch processing, auditory processing, and activity level. According to the answers given, individuals are evaluated in 4 quartiles as low registration, sensory sensitivity, sensation avoiding, and sensation seeking.
Study: NCT06369142

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intravascular lithotripsy (IVL)
Description: Intravascular lithotripsy (IVL) and ballons with a nominal rated burst pressure of ≤ 18 atm
Study: NCT04805073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Promethazine
Description: 1cc 25mg/ml Promethazine (study medication)
Study: NCT06369142

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard non-IVL methods
Description: Standard non-IVL methods treating severely calcified lesions such as special high, super high and cutting balloons and ablative procedures
Study: NCT06070012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tebentafusp
Description: An anti-cancer medication used to treat uveal melanoma. Tebentafusp is a bispecific gp100 peptide-HLA-directed CD3 T cell engager.
Study: NCT06188507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4347859
Description: GSK4347859 will be administered
Study: NCT04805073

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1cc 0.9% Sodium Chloride (placebo)
Study: NCT06249464

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: comprehensive rehabilitation
Description: All the participants were provided with the comprehensive rehabilitation (routine rehabilitation and swallowing function training). The routine rehabilitation included intervention for risk factors (blood pressure, blood lipids, blood glucose, smoking and alcohol restriction, exercise, etc.) and pharmacological treatment (aspirin, statins, anticoagulants, etc.).~Regrading swallowing function training, both groups were given swallowing function training, including 1) exercises of closure of the vocal folds, pharyngeal, and laryngeal muscles exercises, and respiratory muscle strength training, for 15 min each time and twice per day. 2) isotonic／isometric swallowing exercises, supraglottic swallowing exercises, and the Mendelsohn maneuver, for 20 min each time and twice per day. 3) effortful swallowing exercises, and cough reflex training, for 10 min each time and twice per day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: comprehensive rehabilitation
Description: All the participants were provided with the comprehensive rehabilitation (routine rehabilitation and swallowing function training). The routine rehabilitation included intervention for risk factors (blood pressure, blood lipids, blood glucose, smoking and alcohol restriction, exercise, etc.) and pharmacological treatment (aspirin, statins, anticoagulants, etc.).~Regrading swallowing function training, both groups were given swallowing function training, including 1) exercises of closure of the vocal folds, pharyngeal, and laryngeal muscles exercises, and respiratory muscle strength training, for 15 min each time and twice per day. 2) isotonic／isometric swallowing exercises, supraglottic swallowing exercises, and the Mendelsohn maneuver, for 20 min each time and twice per day. 3) effortful swallowing exercises, and cough reflex training, for 10 min each time and twice per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine hydrochloride
Description: the observation group was given SGB once a day, with 10 sessions as a course of treatment and each side of the body for one course. All the materials included: 1) 1.5ml of 2% Lidocaine hydrochloride injection (1ml: 0.5mg), Vitamin B12 Injection 500ug (1ml: 0.5g), the 5 ml disposable syringe and the sterile disposable dental injection needles. The specific operation procedure was as follows\[16\]: The operator stood at the patient\&#39;s block side, and the patient was placed in the supine position, with the head leaning 45 degrees toward the contralateral side of the block side. After routine disinfection of the skin, a paratracheal approach was adopted, which was, 2.5cm above the sternoclavicular joint and 1.5cm outside the midline of the neck.
Study: NCT05712018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch coload - 0 ml/kg
Description: No fluid coload was given. An initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch coload - 5 ml/kg
Description: 5 ml/kg 6% Hydroxyethyl starch (130/0.4) coload combined with an initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch coload - 10 ml/kg
Description: 10 ml/kg 6% Hydroxyethyl starch (130/0.4) coload combined with an initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
Study: NCT05830929

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ovarian tissue freezing and subsequent auto-transplantation after thawing
Description: Removal of the ovarian tissue will be retrieved via laparoscopic surgery under general anesthesia. The ovarian cortical tissue obtained will be transferred on ice to the laboratory for cryopreservation. After medical treatment, if the patient would like to start a family but has experienced premature ovarian failure, she will have ovarian tissue auto-transplantation after thawing.
Study: NCT04931238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS016
Description: Single Intravenous Injection of JS016 with a dose of 50mg/kg
Study: NCT06188507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4347859
Description: GSK4347859 will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4347859
Description: GSK4347859 will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4347859
Description: GSK4347859 will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered